[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2253790A1 - Methods of enhancing anti-tumour immunity in a mammal - Google Patents

Methods of enhancing anti-tumour immunity in a mammal Download PDF

Info

Publication number
CA2253790A1
CA2253790A1 CA002253790A CA2253790A CA2253790A1 CA 2253790 A1 CA2253790 A1 CA 2253790A1 CA 002253790 A CA002253790 A CA 002253790A CA 2253790 A CA2253790 A CA 2253790A CA 2253790 A1 CA2253790 A1 CA 2253790A1
Authority
CA
Canada
Prior art keywords
tumour
cells
combination
interleukin
express
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002253790A
Other languages
French (fr)
Other versions
CA2253790C (en
Inventor
Eva Pizzoferrato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002253790A priority Critical patent/CA2253790C/en
Publication of CA2253790A1 publication Critical patent/CA2253790A1/en
Application granted granted Critical
Publication of CA2253790C publication Critical patent/CA2253790C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anti-tumour immune responses are elicited by engineering genetically lymphoma tumour cells to express interleukin- 12 (IL- 12), the combination of B7-1 and interleukin- 12, or by increasing endogenous expression of the costimulatory molecule B7-2. The combination of B7-1 and IL-12 is most effective in minimal disease settings when the tumour cell engineered genetically to express both molecules is inoculated into the same site of tumour burden. In addition, increasing the expression of endogenous B7-2 provides another method by which anti-tumour immunity is generated against unmodified tumour cells. The mechanisms of the anti-tumour immune response are multifactorial involving T cells as well as natural killer (NK) cells.
CA002253790A 1998-11-25 1998-11-25 Methods of enhancing anti-tumour immunity in a mammal Expired - Lifetime CA2253790C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002253790A CA2253790C (en) 1998-11-25 1998-11-25 Methods of enhancing anti-tumour immunity in a mammal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002253790A CA2253790C (en) 1998-11-25 1998-11-25 Methods of enhancing anti-tumour immunity in a mammal

Publications (2)

Publication Number Publication Date
CA2253790A1 true CA2253790A1 (en) 2000-04-24
CA2253790C CA2253790C (en) 2009-05-05

Family

ID=29425637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253790A Expired - Lifetime CA2253790C (en) 1998-11-25 1998-11-25 Methods of enhancing anti-tumour immunity in a mammal

Country Status (1)

Country Link
CA (1) CA2253790C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150618A4 (en) * 2007-05-04 2011-06-08 Univ Health Network Il-12 immunotherapy for cancer
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
CN114752628A (en) * 2022-05-30 2022-07-15 四川大学华西医院 Construction method and application of C57BL/6 mouse multiple myeloma model

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150618A4 (en) * 2007-05-04 2011-06-08 Univ Health Network Il-12 immunotherapy for cancer
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
EP3293266A1 (en) * 2007-05-04 2018-03-14 University Health Network Il-12 immunotherapy for cancer
US10022405B2 (en) 2007-05-04 2018-07-17 University Health Network IL-12 immunotherapy for cancer
US10258653B2 (en) 2007-05-04 2019-04-16 University Health Network IL-12 immunotherapy for cancer
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
US9439980B2 (en) 2008-03-20 2016-09-13 Univeristy Health Network Thymidylate kinase fusions and uses thereof
US10137205B2 (en) 2008-03-20 2018-11-27 University Health Network Thymidylate kinase fusions and uses thereof
CN114752628A (en) * 2022-05-30 2022-07-15 四川大学华西医院 Construction method and application of C57BL/6 mouse multiple myeloma model
CN114752628B (en) * 2022-05-30 2023-06-30 四川大学华西医院 Construction method and application of C57BL/6 mouse multiple myeloma model

Also Published As

Publication number Publication date
CA2253790C (en) 2009-05-05

Similar Documents

Publication Publication Date Title
CA2259140A1 (en) Method of activating dendritic cells
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
ATE446107T1 (en) IMMUNOGENIC BETA-PROPIONAMIDO-BONDED POLYSACCHARIDE-PROTEIN CONJUGATE SUITABLE AS A VACCINE AND PRODUCED USING N-ACRYLOYLATED POLYSACCHARIDE
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
DE69529219D1 (en) Helicobacter proteine und impstoffe
EP0656788A4 (en) Hla binding peptides and their uses
AU6597998A (en) HLA-A2.1 binding peptides and their uses
EP1917970A3 (en) Hla binding peptides and their uses
HK1009979A1 (en) Generation of xenogeneic antibodies
EP0438803A3 (en) Vaccines against cancer and infectious diseases
EP1923467A3 (en) Adenovirus vectors for gene therapy
AU2821397A (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
CA2135833A1 (en) Antigen carbohydrate compounds and their use in immunotherapy
PL346698A1 (en) Method for down-regulating osteoprotegerin ligand activity
PL323457A1 (en) Vaccine composition containing polyribositoloribitol phosphate and method of obtaining same
MX9707944A (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
CA2253790A1 (en) Methods of enhancing anti-tumour immunity in a mammal
WO2000000588A3 (en) Porcine spinal cord cells and their use in spinal cord repair
TR200002974T2 (en) Live vaccine against brucellosis
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
AU8026800A (en) Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
CA2073778A1 (en) Enzyme treated bcg vaccine and process therefor
EP1089757A4 (en) Hla binding peptides and their uses
EP2147682A3 (en) Vaccination with immuno-isolated cells producing an immunomodulator

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181126